Luteolin as potential treatment for Huntington's disease: Insights from a transgenic mouse model
Luteolin holds promise as a therapeutic agent for improving survival outcomes, managing motor dysfunction, and reducing huntingtin aggregates in HD. The findings are of significance as currently, there are no approved therapeutic interventions that reverse HD pathology or slow down its progression.
Authors
- Nadia Al Mazrouei (ORCID: https://orcid.org/0000-0002-1339-9730)
- Vineetha Menon (ORCID: https://orcid.org/0000-0002-2030-0962)
- Azza Ramadan (ORCID: https://orcid.org/0000-0001-5988-7783)
- Fahad T. Alsulami (ORCID: https://orcid.org/0000-0001-8989-7958)
- Abdulla Al Amoodi
- Ali Awadallah Saeed (ORCID: https://orcid.org/0000-0003-3524-4825)
- Asim Ahmed Elnour (ORCID: https://orcid.org/0000-0002-4143-7810)
- Sami Fatehi Abdalla (ORCID: https://orcid.org/0000-0002-7396-8376)
- Yousef Saeed Alqarni (ORCID: https://orcid.org/0000-0002-4195-3110)
- Abuelnor Mohammed
Institutions
- Alfaisal University (SA)
- Al Ain University (AE)
- Gulf Medical University (AE)
- Taif University (SA)
- University of Sharjah (AE)
- National University (SD)
- Abu Dhabi Health Services (AE)
- Dar Al Uloom University (SA)
- Almaarefa University
- Huazhong University of Science and Technology (CN)
- Imam Abdulrahman Bin Faisal University (SA)
Publication Details
- Journal
- CNS Neuroscience & Therapeutics
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1111/cns.70025
- Citations
- 5
- Primary Topic
- Genetic Neurodegenerative Diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.34